The European Society of Medical Oncology (ESMO) Congress is the most important cancer conference hosted in Europe during the year, and tens of thousands of healthcare professionals will convene in Madrid to learn about and discuss the latest developments in oncology care.
This year’s theme, “integrating science into oncology for a better patient outcome,” is particularly well suited for us as, while we have many pivotal studies reading out over the coming months, our major contribution to ESMO 2017 is in the form of a raft of updates in areas such as biomarker science and diagnostics, and real-world data.
“Progress against cancer is accelerating as our understanding of the disease is enhanced by more sophisticated diagnostics, leading to increasingly tailored treatment approaches,” comments Sandra Horning, MD, our Chief Medical Officer and Head of Global Product Development. “Continuing this progress will require both incremental and ground-breaking advancements as we collectively pursue cures for the many types of this incredibly complex disease. At ESMO, we are proud to share data from across our broad cancer programme and we look ahead to an unprecedented number of key milestones over the next 12 months.”
We will again be present at the congress and we look forward to being a part of the scientific exchange. This year, a total of 18 of our investigational or approved medicines will be featured at the meeting.
We have developed a number of articles to explain how we are working to improve the lives of patients by integrating our cutting-edge science into tomorrow’s standards of care for cancer, which you can find below.